# TMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment Options

> **NCT00115050** · PHASE3 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 260 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** TMC114

## Key facts

- **NCT ID:** NCT00115050
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2011-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00115050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00115050, "TMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment Options". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00115050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*